Skip to main content
SpringerLink
Log in

The Potential Cardiovascular Benefits of COVID-19 Vaccination: Lessons from Influenza and Emerging Evidence

  • Letter to the Editor
  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Kole C, Stefanou Ε, Karvelas N, Schizas D, Toutouzas KP. Acute and post-acute COVID-19 cardiovascular complications: a comprehensive review. Cardiovasc Drugs Ther. 2023;1-16.

  2. Kow CS, Ramachandram DS, Hasan SS. Should COVID-19 be considered cardiovascular disease risk equivalent? Int J Cardiol. 2023;377:123.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Behrouzi B, Bhatt DL, Cannon CP, et al. Association of influenza vaccination with cardiovascular risk: a meta-analysis. JAMA Netw Open. 2022;5(4):e228873.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Kim YE, Huh K, Park YJ, Peck KR, Jung J. Association between vaccination and acute myocardial infarction and ischemic stroke after COVID-19 infection. JAMA. 2022;328(9):887–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Ye X, Yan VKC, Yiu HHE, et al. BNT162b2 or CoronaVac vaccinations are associated with a lower risk of myocardial infarction and stroke after SARS-CoV-2 infection among patients with cardiovascular disease. J Am Heart Assoc. 2023;12(9):e029291.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Funding

The authors declare that no funds, grants, or other support were received during the preparation of this manuscript.

Author information

Authors and Affiliations

  1. School of Pharmacy, International Medical University, Kuala Lumpur, Malaysia

    Chia Siang Kow

  2. School of Pharmacy, Monash University Malaysia, Bandar Sunway, Selangor, Malaysia

    Dinesh Sangarran Ramachandram

  3. School of Applied Sciences, University of Huddersfield, Huddersfield, United Kingdom

    Syed Shahzad Hasan

  4. School of Biomedical Sciences & Pharmacy, University of Newcastle, Callaghan, Australia

    Syed Shahzad Hasan

Authors
  1. Chia Siang Kow
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dinesh Sangarran Ramachandram
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Syed Shahzad Hasan
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

CSK contributed to the conceptualization. The first draft of the manuscript was written by CSK and DSR. SSH revised the draft manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Chia Siang Kow.

Ethics declarations

Competing Interests

The authors have no relevant financial or non-financial interests to disclose.

Ethics Approval

Not applicable.

Consent to Participate

Not applicable.

Consent to Publish

Not applicable.

Competing Interest

All authors declare no conflicts of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kow, C.S., Ramachandram, D.S. & Hasan, S.S. The Potential Cardiovascular Benefits of COVID-19 Vaccination: Lessons from Influenza and Emerging Evidence. Cardiovasc Drugs Ther 38, 421–422 (2024). https://doi.org/10.1007/s10557-023-07485-6

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10557-023-07485-6

Search

Navigation